Tim Harris

Biography

 Dr Harris is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas.  He is a molecular biologist and biochemist, and is currently a Venture Partner with SV Life Sciences.  He was until March 2016, the Senior Vice President (SVP) of Precision Medicine at Biogen.  Before that he was SVP of Translational Medicine at Biogen Idec.  Until 2011, he was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland which operates the National Cancer Institute's Leading centre for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.).  He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised US$85M in capital, and generated more than US$20M in revenue during six years as CEO before it was sold to Eli Lilly.  Before founding SGX, Dr Harris was SVP, Research and Development at Sequana/Axys.  He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.  He is currently on the Board of Directors of Opgen (Nasdaq:OPGN) and is an observer on the Board of SMS-IC in Scotland.  

Research Interest

 Research interest on  Molecular Biology